Drug Trial Radar · NCT05079425
A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Sep 1, 2021
Primary completion
Nov 1, 2022
Study completion Nov 1, 2022
Sponsor
- Lead sponsor
- NEXTGEN BioscienceIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo- controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of NXC736 after oral administration in healthy male volunteers.
Conditions
- Healthy
Interventions
NXC736Drug
Oral administration
PlaceboDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Day 49
- Number of Participants with Serious Adverse Events (SAEs)Time frame: Day 49
- Number of Participants with Vital Sign AbnormalitiesTime frame: Day 49
- Number of Participants with Electrocardiogram (ECG) AbnormalitiesTime frame: Day 49
- Number of Participants with Clinical Laboratory AbnormalitiesTime frame: Day 49
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.